Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2013

View Archived Issues

Researchers establish FNAIT symptoms in mice

Novel OGA inhibitors show efficacy in model of tau aggregation

Retrophin selects new clinical development candidate, RE-034

Gilead Sciences reports data from phase III studies of fixed-dose sofosbuvir and ledipasvir

InSite Vision reports confirmatory phase III data for BromSite

Mylan acquires rights to novel LAMA compound from Pfizer

Merck Serono enters into agreement with the Spanish National Cancer Research Center

Euroscreen begins phase I trial of ESN-364

Biocon and Quark Pharmaceuticals to develop novel siRNA therapeutics

Novel agents for protozoal infections presented by U.S. and Colombian team

Nippon Shinyaku prepares new tyrosine protein kinase inhibitors

Meiji Seika Pharma divulges novel beta-lactamase inhibitors

Takeda Pharmaceutical discloses novel tyrosine-protein kinase inhibitors

Novel botulinum neurotoxin polypeptides prepared by Harvard College

Merck & Co. presents novel PET imaging agents for AD

Atara Biotherapeutics secures funding to accelerate lead program development

AstraZeneca to acquire Bristol-Myers Squibb's diabetes alliance assets

Phase I results demonstrate JNJ-40346527 to be safe in patients with refractory Hodgkin's lymphoma

Crossbeta Biosciences and AdAlta collaborate on i-body technology for Alzheimer's disease

Potent ROR-gamma inverse agonist demonstrates efficacy in a murine model of arthritis

Daiichi Sankyo submits supplemental NDA in Japan for Lixiana

Almirall to acquire Aqua Pharmaceuticals

Cellmid provides data from CK3000 study program

Inavir Dry Powder Inhaler approved for influenza prophylaxis in Japan

NIH announces new preclinical projects under BrIDGs program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...